Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 7,852 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Terminated Phase 3 Interventional Results available

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT00484679
View directory record Official record
Conditions
Alopecia Areata
Interventions
Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 31, 2026, 8:17 PM EDT
Active, not recruiting Not applicable Interventional

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy

NCT04921787
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Interventions
Low Intensity, High Intensity
Other
Lead sponsor
Gavin Bart
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 8:17 PM EDT
Terminated Phase 1 Interventional

tDCS and Cognitive Training for Restrictive Eating Disorders

NCT06624150
View directory record Official record
Conditions
Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions
Active tDCS sessions, StarStim device, Sham (fake) tDCS sessions
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

NCT02603120
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
61
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT01725191
View directory record Official record
Conditions
Childhood Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Tivantinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 31, 2026, 8:17 PM EDT
Terminated Phase 4 Interventional

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

NCT00087620
View directory record Official record
Conditions
Breast Cancer
Interventions
XELODA [capecitabine]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
35
States / cities
Little Rock, Arkansas • Deer Park, California • Greenbrae, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bupropion for the Prevention of Postpartum Smoking Relapse

NCT04098874
View directory record Official record
Conditions
Postpartum Smoking Relapse
Interventions
Bupropion Extended Release Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

NCT01926782
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Statin
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

NCT00606268
View directory record Official record
Conditions
Fungal Infections
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 16 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 31, 2026, 8:17 PM EDT
Recruiting No phase listed Observational

Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures

NCT04604418
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
No intervention. It is observational
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis

NCT00171665
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac topical sodium gel 1%
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
69
States / cities
Birmingham, Alabama • Calera, Alabama • Montgomery, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Debio 1562, Rituximab
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FF, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 31, 2026, 8:17 PM EDT
Recruiting Phase 2 Interventional

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

NCT05305911
View directory record Official record
Conditions
Heart Attack, Enlarged Heart
Interventions
SGLT-2 inhibitors, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion

NCT02981407
View directory record Official record
Conditions
Myocardial Infarction, Anemia
Interventions
Red Blood Cell Transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
60
States / cities
Little Rock, Arkansas • Los Angeles, California • Danbury, Connecticut + 48 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

NCT00677365
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
MP-376, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
16 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT00113165
View directory record Official record
Conditions
Epilepsy, Epilepsy, Partial
Interventions
LAMICTAL extended-release
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

NCT00059865
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
41
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

NCT01333111
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 31, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

NCT00756730
View directory record Official record
Conditions
HIV Infections
Interventions
ATV/r, DRV/r
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 31, 2026, 8:17 PM EDT